Articles On Imugene (ASX:IMU)

Title Source Codes Date
Closing Bell: Today’s biggest small cap movers on the ASX

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Stockhead IMU 1 day ago
April Winners Column: Resources re-takes the mantle, led by one stock that gained nearly 500pc

Google April 2021 and the first things you’ll find isn’t ASX winners but questions about COVID-19. Just another month in the pandemic, right? Well, yes and no. On one hand the vaccine race continues across the world – far slower than we’d l...

Stockhead IMU 1 day ago
Imugene has HER-Vaxx Phase 1B Data published in prestigious clinical cancer research journal

HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

Proactive Investors IMU 1 week ago
Imugene achieves phase-II clinical trial milestone for HER-Vaxx cancer immunotherapy

The important clinical endpoint of Progression Free Survival (PFS) has been met after the statistically significant required number of PFS events has occurred.

Proactive Investors IMU 2 weeks ago
Australia…1 hour in… ASX200 down 65

ShareCafeAustralia…1 hour in… ASX200 down 65 ASX200 down 65 points (0.9%) to 6952.   BHP (-1.8%); reported a 7% drop in Q Iron Ore shipments but still sees FY iron ore output near upper end of forecast. Challenger (-6.4%); still feeling un...

ShareCafe IMU 2 weeks ago
Imugene CEO hails clinical milestone for HER-Vaxx cancer immunotherapy

Proactive Investors IMU 2 weeks ago
Imugene shares up 6pc on after ‘milestone’ for cancer vaccine

Imugene shares have hit a fresh all-time high this morning after the Sydney biotech said its HER-Vaxx cancer vaccine had achieved a clinical milestone in a phase 2 gastric cancer trial. The 36-patient trial met its secondary endpoint of imp...

Stockhead IMU 2 weeks ago
Why Brickworks, Imugene, Platinum, & Synlait shares are dropping today

In afternoon trade on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a disappointing decline. At the time of writing, the benchmark index is down 0.35% to 6,970.7 points. Four ASX shares that are falling m...

Motley Fool IMU 3 weeks ago
Imugene says 2021 has been 'stellar year so far' as it rapidly advances anti-cancer programs

Proactive Investors IMU 3 weeks ago
Australia…1 hour in… ASX200 down 11

ShareCafeAustralia…1 hour in… ASX200 down 11 ASX200 down 11 points (0.2%) to 6893   BHP (-0.2%); said the decision by its Brazilian joint venture with Vale SA to file for judicial reorganization is a last-resort response to legal actions f...

ShareCafe IMU 3 weeks ago
Hot Money Monday: Asian American Medical Group is the most in-demand stock on the ASX right now

Singapore-based Asian American Medical Group (ASX:AAJ) was among the small cap names that ran red hot this week. Stockhead’s Hot Money Monday analysis is based on the Relative Strength Index (RSI) — a technical gauge which measures how trad...

Stockhead IMU 3 weeks ago
ScoPo’s powerplays: Antisense ‘looks like it wants to run harder’

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The ASX he...

Stockhead IMU 3 weeks ago
Last Orders: Sixth straight day of gains for small caps

Small caps have gained for a sixth straight day, even as their larger peers declined. The Small Ordinaries index of Australia’s 101st to 300th biggest companies finished the week up 6.7 points, or 0.2 per cent, to a fresh 13-year high of 3,...

Stockhead IMU 3 weeks ago
Closing Bell: Today’s biggest small cap movers on the ASX

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

Stockhead IMU 4 weeks ago
Imugene (ASX:IMU) to proceed to final dose cohort for lung cancer treatment

07 Apr 2021 - $620 million cancer treatment provider Imugene (ASX:IMU) has announced that an independent team of researchers have certified that lung cancer drug PD1-Vaxx is safe f…

FNN IMU 4 weeks ago
Imugene gains 10pc on cancer vaccine progress; 3 other biotechs getting patents

Imugene (ASX:IMU) shares have hit an all-time high after the Sydney biotech company announced its cancer vaccine was continuing to show early promise in a small clinical trial. A cohort review committee has allowed the Phase 1 trial to move...

Stockhead IMU 4 weeks ago
Why the Imugene (ASX:IMU) share price just hit an all-time high

The Imugene Limited (ASX: IMU) share price is through the roof today, breaking record highs. At the time of writing, shares in the medical research and development company are up 11.5%, trading at a record high of 14.5 cents each. By compa...

Motley Fool IMU 4 weeks ago
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Stockhead IMU 1 month ago
ASX 200 marginally lower as S&P ASX 200 Quarterly Rebalance Released

Source: Enjoy The Life, Shutterstock Summary ASX 200 increased 0.8% on Friday, however it edged lower Monday morning with a decline of almost 33% following the quarterly rebalance announcement. ASX 200 saw 6 new companies being added...

Kalkine Media IMU 1 month ago
Why the Imugene (ASX:IMU) share price is lifting 5% higher

The Imugene Limited (ASX: IMU) share price is on the move today. This comes after the company announced an update on its Phase 1 clinical trial of its immunotherapy candidate, PD1-Vaxx. PD1-Vaxx is a B-cell immunotherapy designed to treat...

Motley Fool IMU 2 months ago
Imugene doses first patient in cohort-2 in phase-I clinical trial of PD1-Vaxx

The company is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

Proactive Investors IMU 2 months ago
Here’s why the Imugene (ASX:IMU) share price is rising 9% today

The Imugene Limited (ASX: IMU) share price is on the rise today. This comes after the company received a successful outcome from the Cohort Review Committee (CRC) regarding its PD1-Vaxx immunotherapy. PD1-Vaxx is a B-cell immunotherapy des...

Motley Fool IMU 3 months ago
Imugene receives approval for phase I clinical trial of new checkpoint immunotherapy candidate PD1-VAX

The CRC unanimously agreed that PD1-Vaxx is safe with no dose-limiting toxicities (DLTs) and has recommended to proceed to the next dose escalation due to safety and tolerability.

Proactive Investors IMU 3 months ago
Imugene's Leslie Chong details dose escalation for its phase I clinical trial of PD1-Vaxx

Proactive Investors IMU 3 months ago
Chimeric Therapeutics (ASX:CHM) shares surge ~48% on Day 1 on the ASX

Summary Chimeric Therapeutics commenced trading on the ASX today following the successful completion of its IPO. The drug development company raised almost A$35 million from Institutional as well as sophisticated investors. The Compan...

Kalkine Media IMU 3 months ago
Here’s Why Imugene (ASX:IMU) Grabbed Headlines on Thursday

Summary Imugene Limited (ASX:IMU) has completed the recruitment of patients under its ongoing HER-Vaxx Phase 2 clinical trial. Imugene has reduced the overall number of patients under Phase 2 trial to 36 following the IDMC guidance. T...

Kalkine Media IMU 3 months ago
Imugene Share Price Climbs 5% as Cancer Trial Closer to Commencing

Imugene Ltd [ASX:IMU] certainly finished 2020 with a bang. With a 5% lift in the IMU share price this morning, the stock is making waves once more. Today, it has since eased back from those record highs, but it is still faring well... The p...

MoneyMorning IMU 3 months ago
Why did the Imugene (ASX:IMU) share price jump 5% this morning?

Imugene Limited (ASX: IMU) shares have jumped by 5% in trading so far today after the biotechnology company announced it has completed recruitment for its HER-Vaxx Phase-2 gastric cancer trial. At the time of writing, the Imugene share pri...

Motley Fool IMU 3 months ago
Australia…One Hour In…ASX up 85 points

ShareCafeAustralia…One Hour In…ASX up 85 points ASX200 up 85 points (1.3%) to 6692. Market tracking better on prospects for more US stimulus after the Democrats won control of the Senate.  Disturbingly,  the focus this morning has been on t...

ShareCafe IMU 3 months ago
Imugene completes recruitment to HER-VAXX Phase 2 gastric cancer trial

The Phase 2 trial represents a clinical proof-of-concept for HER-Vaxx to indicate that B-cell activating immunotherapy platform can induce clinically active antibody responses.

Proactive Investors IMU 3 months ago
Why the Rhythm Biosciences (ASX:RHY) share price jumped over 600% this year

The Rhythm Biosciences Ltd (ASX:RHY) share price has rocketed over 640% for the past twelve-month period. From the beginning of November alone, the share price has soared over 355%.  For the past few weeks, we’ve been watching Rhythm Biosc...

Motley Fool IMU 4 months ago
Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

Summary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first cohort under PD1-Vaxx Phase I clinical trial. Following the Phase I trial, a monotherapy optimal biological dose will be determined through a r...

Kalkine Media IMU 4 months ago
Imugene completes enrolment of first cohort of patients in Phase I clinical trial of checkpoint immunotherapy candidate PD1-Vaxx

The clinical-stage immune-oncology company has enrolled the first three patients in the first low dose PD1-Vaxx cohort with non-small cell lung cancer.

Proactive Investors IMU 4 months ago
Imugene (ASX:IMU) Receives $4.82 million R&D Tax Incentive, Moves Swiftly with Clinical Trials

Summary Imugene Limited (ASX:IMU) has received an R&D tax refund of ~$4.82 million under government’s R&D tax incentive. The tax incentive is expected to support Imugene in its commercial and clinical milestones. Imugene has r...

Kalkine Media IMU 4 months ago
Imugene boosts cash balance after receiving $4.82 million R&D tax incentive

Receiving the $4,823,466 million in additional funding will further support the company's commercial and clinical milestones.

Proactive Investors IMU 4 months ago
Imugene Limited phase II trial is highly encouraging: Bell Potter Securities

Bell Potter has raised its valuation of Imugene to 17 cents from 5 cents and has maintained its buy (speculative) recommendation.

Proactive Investors IMU 4 months ago
Imugene (ASX:IMU) Zooms Up 8%; Doses 1st Patient Under PD1-Vaxx Phase 1 Trial in Australia

Summary Imugene Limited (ASX:IMU) has dosed its first patient in PD1-Vaxx Phase 1 trial in Melbourne. An optimal biological dose as a monotherapy will be determined after review by Imugene’s Cohort Review Committee. Imugene intends to...

Kalkine Media IMU 5 months ago
Imugene CEO says PD1-Vaxx could be 'paradigm shift' in oncology

Proactive Investors IMU 5 months ago
First patient dosed with Imugene’s lung cancer drug candidate

Sydney biotech company Imugene (ASX:IMU) says it has dosed its first patient with its drug candidate PD1-Vaxx, a checkpoint immunotherapy ... Read More The post First patient dosed with Imugene’s lung cancer drug candidate appeared first on...

Stockhead IMU 5 months ago
Australia…One Hour In…ASX up 33 points

ShareCafeAustralia…One Hour In…ASX up 33 points ASX200 up 33 points (0.5%) to 6551. AUB (-1.6%); will acquire 360 Underwriting Solutions for $127m. Collins Foods (+4.2%); 1H profit +15%.   Strong result. Domino’s Pizza (+11%); Investor Day...

ShareCafe IMU 5 months ago
Imugene doses first patient in Phase 1 clinical trial of checkpoint immunotherapy candidate PD1-Vaxx for lung cancer

The first-in-human, Phase 1, multi-centre, dose-escalation study of PD1-Vaxx is recruiting patients with non-small cell lung cancer.

Proactive Investors IMU 5 months ago
Imugene Limited’s (ASX:IMU) HER-Vaxx Delivers Promising Results in Phase 2 Interim Analysis

Summary Imugene Limited (ASX:IMU) has recently shared promising interim data from its continuing Phase 2 trial of HER-Vaxx. The interim analysis results demonstrated that twice as many patients survived on the HER-Vaxx plus SOC chemoth...

Kalkine Media IMU 5 months ago
Why the Imugene (ASX:IMU) share price has soared over 300% this year

The share price of biotechnology company Imugene Limited (ASX: IMU) has been on a tear this year. Imugene shares are up another 13% today at the time of writing, meaning the share price has soared over 300% in the year to date. With a marke...

Rask Media IMU 5 months ago
Imugene Share Price Lifts as Fresh Results Show Promise (ASX:IMU)

The Imugene Ltd [ASX:IMU] share price is trading 15% higher at time of writing. Rising on the back of new news from the biotech’s phase 2 trial. In what is now just the latest leg up for the company in the past month... The post Imugene Sha...

MoneyMorning IMU 5 months ago
Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform'

Proactive Investors IMU 5 months ago
Imugene up 20% on unveiling positive interim data from ongoing Phase 2 study of HER-Vaxx in advanced gastric cancer

The IDMC provided guidance that it is scientifically and ethically appropriate to reduce the overall number of patients required to complete the study, given the strong signal observed in the data.

Proactive Investors IMU 5 months ago
Imugene (ASX:IMU) Wins FDA IND Approval to Kick Off PD1-Vaxx’s Phase 1 Trial in US

Summary Imugene has received the US FDA IND approval to kick-start Phase 1 clinical trial of PD1-Vaxx in the US. The FDA approval enables Imugene to commence patient dosing and recruitment in its Phase 1 clinical trial in the US in non-...

Kalkine Media IMU 6 months ago
Imugene CEO says FDA IND approval for PD1-Vaxx is 'huge news' for the company

Proactive Investors IMU 6 months ago
Australia…One Hour In…ASX Up 6 Points

ShareCafeAustralia…One Hour In…ASX Up 6 Points ASX200 up 6 points (0.1%) to 5933. – AMP (+8.6%); says the Ares takeover proposal implies a value of $1.85 a share. Trading @ $1.65.– IAG (-0.8%); CEO Mark Milliner to leave. Nick Hawkins new C...

ShareCafe IMU 6 months ago
Imugene receives FDA IND approval for phase-1 clinical trial of new checkpoint immunotherapy PD1-Vaxx in USA

US FDA approval of the IND allows Imugene to initiate patient recruitment and dosing in its USA Phase I clinical study in non-small cell lung cancer (NSCLC) patients.

Proactive Investors IMU 6 months ago